| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change | | --- | --- | --- | --- | --- | | EPS (GAAP) | $0.16 | $0.14 | $0.20 | (20.0%) | | Revenue | $264.6 million | $262.0 million | N/A | N/A | | Net Product Sales – NUPLAZID | $168.5 million | | $157.4 million | 7.0% | | Net Product Sales – DAYBUE | $96.1 million | | N/A | N/A | | Research & Development Expenses | $78.0 million | | $76.2 million | 2.4% | | Selling, General & Administrative Expenses | $133.5 million | | $117.1 million | 14.0% | Acadi ...